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Abstract
Background: The spread of multidrug-resistant (MDR) and extensively drug-resistant (XDR) Mycobacterium tuberculosis
compromises effective control of tuberculosis (TB) in Siberia. Early identification of drug-resistant isolates is, therefore,
crucial for effective treatment of this disease. The aim of this study was to conduct drug susceptibility testing and
identify mutations in drug resistance genes in clinical isolates of M. tuberculosis from some TB patients presenting for
treatment in Siberia.
Methods: Thirty randomly selected clinical isolates of M. tuberculosis were obtained from the Novosibirsk Research
Institute of Tuberculosis, Russia. Isolates were screened for drug resistance and characterized by variable number of
tandem repeats (VNTR)-typing using 15 standard and four additional loci. Deligotyping on multiple large sequences
was performed using 10 loci.
Results: Twenty-nine of the isolates were assigned XDR status. Twenty-eight isolates belonged to the M. tuberculosis
Beijing family, from which 11 isolates were considered the M11 type (39%), two the M2 type (7%), and one the M33
type (3%). Seventeen isolates (60.7%) from this family exhibited unique genetic patterns. The remaining two isolates
belonged to the Latino-American Mediterranean family. Gene sequences (rpoB, katG, rrs, rpsL, tlyA, gidB, gyrA, gyrB) were
analyzed to identify mutations that confer resistance to rifampicin, isoniazid, amikacin, kanamycin, capreomycin, and
ofloxacin. The most common mutations among the XDR isolates were S531L in RpoB, S315T in KatG, various codon 94
mutations in gyrA, A90V in GyrA, K43R in RpsL, and 1401 A→ G in rrs; these confer resistance to rifampicin, isoniazid,
ofloxacin, streptomycin and kanamycin/capreomycin, respectively. There was high congruence between the two typing
methods (VNTR typing and deligotyping) and RD105, RD149, RD152, RD181, and RD207 regions of difference were
absent from the 28 Beijing family isolates.
Conclusions: Deligotyping can be used for rapid and reliable screening of M. tuberculosis isolates, followed by more
in-depth genotyping. Identification of Beijing family isolates with extensive drug resistance confirms that such strains
have epidemiological importance in Siberia. Rapid detection of mutations that lead to drug resistance should facilitate
selection of effective drug therapies, and the development of early prevention strategies to combat this infection.
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Background
The dissemination of extensively drug resistant (XDR)
Mycobacterium tuberculosis poses a threat to the fight
against tuberculosis (TB). According to a 2012 WHO re-
port, XDR-TB has been identified in 84 countries where it
comprises 9% of all cases that are multidrug resistant
(MDR) [1] from a worldwide figure of 310,000 in 2011.
From this, 60% of all MDR-TB cases were from Russia,
India, China, and South Africa. In Russia in particular, the
number of cases with a confirmed diagnosis of MDR-TB in
2011 was 44,000 [1], while the 2011 Novosibirsk Research
Institute of Tuberculosis report for the Novosibirsk region
of Russia revealed that the number of cases with primary
MDR- and XDR-TB was 272 (28.7%) and 4 (0.4%), respect-
ively. What is particularly alarming is that the rapid in-
crease in MDR-TB in the Novosibirsk region, which in
2005 was 43/100,000, and in 2011 was 58.3/100,000 of the
population. In Siberia from 2005 to 2011 the increase was
from 34.0 to 46.5/100,000 of the population, while the Far
Eastern Federal Districts rose from 20.0/100,000 to 38.3/
100,000 of the population.
The causes of XDR TB are multi-factorial and include
incorrect treatment regimens, violations of chemotherapy
regimens, late diagnosis, and poor infection control [2].
M. tuberculosis can rapidly accumulate non-synonymous
mutations in genes associated with the emergence of drug
resistance. The term XDR itself relates to the involvement
of simultaneous resistance to first-line drugs (e.g., isonia-
zid and rifampicin), one of the injectable second-line
drugs (e.g., amikacin, capreomycin, and kanamycin), and
any of a number of ofloxacin-based drugs. Rifampicin re-
sistance in M. tuberculosis is caused by mutations in the
core region of the rpoB gene, while isoniazid resistance is
associated with mutations in the katG, inhA, ahpC, and
oxyR genes [3]. Other anti-TB drugs for which resistance
has developed include ethambutol (involving mutations in
the embAB locus), streptomycin (involving nucleotide
changes in the gidB and rpsL genes) [4], ofloxacin (involv-
ing the gyrA and gyrB genes), and amikacin and capreo-
mycin (involving the rrs gene encoding 16S rRNA, and
also in the tlyA gene encoding hemolysin) [5].
The aims of this study were to: 1) genotype and
characterize multidrug resistance in M. tuberculosis iso-
lates using an extended set of loci for variable number of
tandem repeats (VNTR)-typing and by deligotyping; and
2) detect the spectrum and frequency of mutations associ-
ated with the emergence of XDR inM. tuberculosis.
Methods
M. tuberculosis isolates
This was a cross-sectional study, examining the drug sus-
ceptibility and molecular-genetic features of XDR isolates
in Siberia and Far East of Russia. The Novosibirsk Re-
search Institute of Tuberculosis (NRIT) acts as the
national referral center for TB in Far East and Siberia re-
gion of Russia. Under the National Tuberculosis Control
program, randomly selected patients with the MDR and
relapse tuberculosis are referred to the NRIT for evalu-
ation and treatment. 372 MDR isolates (31 XDR) were re-
covered from January 2011 to February 2012. We
analyzed 30 consecutive XDR-TB clinical isolates corres-
pond to 1.6% of all the XDR-TB ones isolated in Far East
and Siberia region of Russia. All analysed MTB were re-
covered from individual patients with pulmonary TB who
were treated at NRIT from January 2011 to February 2012
were included in study. Despite small size of tested sample
set percentage of XDR among MDR isolates (8%) did not
showed statistically significant differences (p-value = 0.76)
with total one in supervised region (1858 XDR/24400
MDR during the same period of time). All isolates were
obtained from patients already receiving TB treatment for
more than 1 month. Only three patients were treated for
less than 1 month. Fourteen patients were admitted to
hospital from the Novosibirsk region, two from the Re-
public of Khakassia, two from Kemerovo Oblast, two from
Omsk Oblast, two from Krasnoyarsk Krai, two from Kam-
chatka, and one each from Tomsk, Tuva Republic, the
Jewish Autonomous Region, Chita, and Altai Republic.
This study had bioethical approval from the local commit-
tee on medical ethics. Informed consent was received
from each patient in the study.
Bacterial culture and antibiotic susceptibility testing
Drug resistance was determined by calculating the
minimal inhibitory concentrations (MIC) using the Bactec
MGIT 960 system (BD, New Jersey, USA) with standard
concentrations of drugs as follows: isoniazid (0.1 μg/ml),
rifampicin (1 μg/ml), pyrazinamide (100 μg/ml), strepto-
mycin (1 μg/ml), ethambutol (5 μg/ml), kanamycin
(1 μg/ml), amikacin (1 μg/ml), ethionamide (5 μg/ml),
ofloxacin (2 μg/ml), and capreomycin (2.5 μg/ml).
DNA extraction
DNA was isolated from M. tuberculosis cultures at
NRIT, as described previously [6].
PCR amplification and DNA sequencing of genes
associated with drug-resistance
PCR amplification was performed in 20-μl volumes con-
taining 65 mM Tris–HCl (pH 8.9), 16 mM (NH4)2SO4,
0.05% Tween 20, 2.5 mM MgCl2, 0.1 mM dNTPs, 1 μM
gene-specific oligonucleotide primers (Table 1), 1 U Taq
DNA polymerase, and 1–10 ng ofM. tuberculosis genomic
DNA. The oligonucleotide primer sequences are shown in
Table 1. Reactions were carried out in a Tertsik amplifier
(DNA Technology, Russia) using an initial denaturation
step of 96°C for 3 min, followed by 38 cycles of denatur-
ation at 95°C for 10 s, annealing at 64°C for 10 s, and
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elongation at 72°C for 20 s, with a final elongation step at
72°C for 3 min. The presence of an amplification product
was verified by 6% PAGE with subsequent visualization of
the DNA by ethidium bromide staining. PCR products
were sequenced in SB RAS Genomics Core Facility ac-
cording to the manufacturer’s instructions using a Big Dye
Terminator v3.1 Cycle Sequencing Kit (Life Technologies
Corp., Carlsbad, CA) with the same primers used for PCR
and run on an ABI PRISM 3130xl Genetic Analyzer (Life
Technologies.). Mutations were detected in the genes by
comparison with the M. tuberculosis wild-type reference
laboratory strain (H37Rv) using Unipro UGENE software
(version 1.11.3) (http://ugene.unipro.ru/).
VNTR-typing
VNTR typing of ETR-A, ETR-B, ETR-C, MIRU 2, MIRU4,
MIRU10, MIRU16, MIRU20, MIRU23, MIRU24, MIRU26,
MIRU27, MIRU31, MIRU39, MIRU40, Mtub30, Mtub39,
QUB4156, and V11 loci was performed by PCR in a
volume of 20 μl containing 65 mM Tris–HCl (pH 8.9),
23 mM (NH4)2SO4, 3 mM MgCl2, 0.05% Tween 20,
0.2 mM dNTPs, 1 μM loci-specific oligonucleotide
primers, 1 U Taq DNA polymerase and 1–10 ng of M. tu-
berculosis genomic DNA, as described previously [7,8].
The oligonucleotide primer sequences are shown in
Table 1. Reactions were carried out in an iCycler amplifier
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(Bio-Rad, California, USA) where, after an initial denatur-
ation step of 96°C for 3 min, 38 cycles were performed as
follows: denaturation at 95°C for 10 s, annealing at 60°C for
10 s, elongation at 72°C for 30 s, and a final elongation at
72°C for 3 min. The presence of an amplification product
was checked by 6% PAGE with subsequent visualization of
the DNA by ethidium bromide staining. The number of
tandem repeat copies was calculated as a function of the
size of the PCR product. The structure and number of re-
peat copies was also verified selectively by direct sequen-
cing of the amplified DNA fragments. The genotype of
each isolate was expressed as a set of 19 digits where each
digit showed the number of copies of the corresponding
tandem repeat.
Deligotyping
Deligotyping was performed as described previously
[9,10]. Typing was performed by real-time PCR in a
20 μl volume containing 10 mM Tris-НСl (рН 8.9),
2.5 mM MgCl2, 0.2 mM dNTPs, 55 mM KCl, 0.05%
Tween 20, 1 U Taq DNA polymerase, and 1–10 ngM.
tuberculosis genomic DNA. SybrGreen I (supplied as a
10 000 × solution; Life Technologies), was used at a final
concentration of 0.2 ×. The oligonucleotide primer se-
quences are given in Table 1. Reactions were carried out
in an iCycler iQ5 (Bio-Rad) with initial denaturation step
of 96°C for 3 min, followed by 40 cycles of denaturation
at 96°C for 10 s, annealing at 62°C for 20 s, and elong-
ation at 72°C for 10 s, with data acquisition at 72°C on
the SYBR channel (excitation at 470 nm; detection at
585 nm using a high pass filter) and melting curves for
the amplified products from 82°C to 96°C (in 0.2°C
increment).
Statistical analysis
Statistical data processing was performed using STATIS-
TICA 6.0 (StatSoft, www.statsoft.com). Cluster analysis and
dendrogram construction were performed using UPGMA
and the neighbor-joining method. To determine the con-
gruence of the two methods, the Rand coefficient was used
[11]. The cut-off for significance was taken as P < 0.05. The
minimum spanning tree (MST) was built using the eBurst
algorithm [12]. The Hunter–Gaston Discrimination Index
(HGDI) was used as an estimate of the allelic diversity for
specific areas in the 19 combined loci [13].
Results
Sample description
In our dataset, the patients were aged 20 to 61 (mean
34.9 ± 10.9), with males comprising 58.6%. In Table 2, we
introduced artificially age ranges: the minimum value plus
one, two and so on standard deviations, obtain several age
ranges (20–30,9 (I); 30.9 - 41.8 (II); 41.8 - 52.7 (III); 52,7 –
63, 6 (IV)). Six patients had primary tuberculosis; the
others had chronic tuberculosis, where a reinfection or re-
activation had occurred. Isolates 133 and 236 were
obtained from one patient. Regarding the diagnosis of
tuberculosis, patients were divided as follows: fibro-
cavernous tuberculosis (17), infiltrative tuberculosis (7),
disseminated tuberculosis (3), and caseous pneumonia (2).
Only six patients had no comorbidities. Some patients had
two or more diseases; for example, hepatitis C was de-
tected among 10 patients (among them one patient had
hepatitis B, while two had HIV), bronchitis affected nine
patients, different diseases of the gastrointestinal tract af-
fected eight patients, diabetes affected one. Five patients
were connected with penitentiary systems, 12 patients had
earlier contact with TB patients, of whom eight had family
contact. Tuberculosis was diagnosed in 20 patients treated
by the general health services, whereas nine cases were
obtained from preventive examinations (Table 2).
Only five patients had no complaints at the time of ad-
mission to the NRIT (isolates 78 and 285). The other pa-
tients complained of cough, shortness of breath, fever, and
weight loss. Lesions in the lungs, from single to multiple,
and from small to giant size, were detected radiographically.
The disintegration of lung-tissues was not detected in one
case, but the progression of tuberculosis disease was repeat-
edly observed in the form of increasing infiltration size
(isolate 37). All patients had smear-positive tuberculosis.
All cases with identified isolates of the M. tuberculosis
Latino-American Mediterranean (LAM) family (isolates 15
and 48) were characterized by unfavorable epidemiological
histories: one patient was infected in prison, while the sec-
ond patient worked three years as a nurse in a morgue and
was involved in autopsies.
Drug-susceptibility patterns
Using conventional methods, it was shown that all 30
isolates were multidrug-resistant TB (MDR-TB, i.e. re-
sistant to at least isoniazid and rifampicin); of these, 29
(96,6%) were characterized as extensively drug-resistant,
while 10 (33%) were resistant to all of the drugs that
were tested.
Mutations identified in the rpoB, katG, rrs, tlyA, gidB, rpsL,
gyrA, gyrB, and pncA genes
Mutations in the rpoB, katG, rrs, tlyA, gidB, rpsL, gyrA,
gyrB, and pncA genes were used as markers of the drug
resistance phenotypes in the isolates. Sequence analysis
of selected isolates of M. tuberculosis identified the mu-
tations shown in Table 3.
The presence of a mutation in codon 531 of the rpoB
gene, which encodes the β-subunit of RNA polymerase
and is involved in rifampicin resistance, was found in 27
of the 30 isolates (90%). In particular, among 12 isolates
it was the only mutation present in this gene, while the
other 14 isolates harbored S531L and S540R mutations.
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Table 2 Initial data on the investigated 30 clinical isolates M.tuberculosis observed among 29 tuberculosis patients




Sex DS Comorbidities Epidemic history Complaints
6 2 1 1 1 1 1 1 1 1 1 1 2 I f FCPT No Family Cough
9 1 1 1 0 0 1 1 1 1 1 1 2 III m FCPT No Prison Cough, shortness of breath
15 3 1 1 1 1 1 1 1 1 1 1 2 II m FCPT HCV, drug addiction Prison Cough, shortness of breath,
fever,
17 2 1 1 1 1 0 0 1 1 1 1 2 I f FCPT Chronic bronchitis Family Cough, hemoptysis
20 4 1 1 1 0 0 1 0 1 0 1 2 II f IPT No Professional
(the nurse)
Cough
21 3 1 1 0 1 1 1 1 1 1 1 1 I m IPT Chronic gastritis No Weakness, sweating, fever,
hemoptysis
37 3 1 1 1 0 0 1 1 1 1 1 2 II f IPT Neurocirculatory dystonia, encephalopathy, cervical





38 9 1 1 1 1 0 0 1 1 1 1 2 I f DPT No Family Shortness of breath, weakness




78 3 1 1 1 1 1 0 0 1 1 1 2 II f FCPT HCV Family No
87 3 1 1 0 0 0 0 1 1 1 0 1 I f FCPT Bronchitis after postural drainage Family Shortness of breath
94 5 1 1 1 1 1 1 1 1 1 1 2 II f FCPT Obstructive bronchitis, bronchial asthma, syphilis No Cough, weakness, shortness of
breath
96 4 1 1 1 1 1 0 0 1 1 1 2 I f FCPT HCV Family Weaknwss, chest pain
128 6 1 1 1 0 1 1 1 1 1 1 2 I m FCPT Duodenal ulcer No Cough
133 7 1 1 1 0 0 1 1 1 1 1 2 II m FCPT Chronic pancreatitis No Cough
145 3 1 1 0 1 1 1 1 1 1 0 2 II m IPT HCV, drug addiction Prison (1998–2001) Cough
158 3 1 1 1 1 1 1 1 1 1 0 1 I m IPT No No Cough, shortness of breath,
sweating
169 6 1 1 1 1 0 1 1 1 1 1 2 I f FCPT Respiratory failure 1 level, chronic adnexitis No Cough, fever, hemoptysis
171 3 1 1 1 1 0 0 0 1 1 1 2 I m FCPT Secondary bronchial obstruction, respiratory failure 2,
heart failure, cachexia
No Cough, shortness of breath,
weakness, chest pain, weight
loss
235 3 1 1 1 1 1 0 1 1 1 1 1 IV m CP Diabetes, steatohepatitis, chronic cholecystitis,
cholelithiasis
No Cough, shortness of breath,
weakness
236 7 1 1 1 1 1 1 1 1 1 1 2 II m FCPT Chronic pancreatitis No Cough
238 3 1 1 1 1 1 1 1 1 1 1 2 IV m FCPT Obstructive bronchitis, emphysema, heart failure No Shortness of breath
275 8 1 1 1 1 1 1 1 1 1 1 1 I f FCPT HCV, bronchitis Contact with
neighbors
Cough, weakness, shortness of
breath





















Table 2 Initial data on the investigated 30 clinical isolates M.tuberculosis observed among 29 tuberculosis patients (Continued)
285 8 1 1 1 1 1 1 1 1 1 1 2 II m FCPT HCV Prison (2007–2009) No
287 3 1 1 1 1 1 1 1 1 1 1 2 II m IPT HIV, HCV, sinusitis, stomatitis, drug addiction No Cough, shortness of breath,
weakness, sweating
300 11 1 1 0 0 1 1 1 1 1 0 2 II m FCPT Obstructive bronchitis Prison Cough, fever, chest pain
309 3 1 1 1 1 1 0 1 1 1 1 2 II m IPT HIV, HCV, drug addiction Contact with
neighbors
Cough with sputum
1084 8 1 1 1 1 1 1 1 1 1 1 2 I m CP Obstructive bronchitis Family Cough, chest pain
4548 3 1 1 1 1 0 1 1 1 1 1 2 IV f FCPT Obstructive bronchitis, hypertonic disease II Death Shortness of breath, tiredness
Note: In the column ‘region’ numbers denote: 1 - Jewish Autonomous Oblast, 2 – the Krasnoyarsk Kray, 3 – Novosibirsk region, 4 – Omsk Oblast, 5 – Chita city, 6 - Kemerovo oblast, 7 – Kamchatka, 8 - The Republic of
Khakassia, 9 – The Tuva Republic, 10 - Tomsk, 11 - Altay Republic. Resistance to anti-TB drugs: 1 - resistant, 0 - sensitive. Designation column: S - streptomycin, H - isoniazid, Et - ethionamide, E - ethambutol,
CAP - capreomycin, A - amikacin, K-kanamycin, R - rifampicin, Of - ofloxacin, Z - pyrazinamide. In the column “ duration of illness”: 1 - primary tuberculosis, 2 - secondary tuberculosis. In the column «DS» - diagnosis:





















Table 3 Mutations in rpoB, katG, gidB, pncA, gyrA, gyrB, rpsL, rrs, and tlyA genes associated with the formation of drug resistance and the following amino acid
substitutions
№ rpoB katG gidB pncA gyr A gyrB rpsL rrs tlyA
6 S531L, S540R S315T E92D A-11G S95T No mutation K43R 1401 A → G L11L
9 S531L, S540R S315T E92D I5T D94A, S95T No mutation K43R 1401 A → G, DelA 1473396 L11L
15 S531L, S540R S315T L10R T-7C D94N, S95T No mutation No mutation 1401 A → G, 685 G → A L11L
17 S531L, S540R S315T E92D 48InsG D94H, S95T No mutation K43R No mutation L11L
20 L511P, D516G, S540R S315T E92D L4W S95T No mutation No mutation No mutation L11L
21 S531L, S540R S315T E92D Y99STOP A90V, S95T No mutation K43R 1401 A → G L11L
37 S531L, S540R S315T E92D T76P D94A, S95T No mutation K43R No mutation L11L
38 S531L, S540R S315T E92D L120P D94E, S95T No mutation K43R 1401 A → G L11L
48 D516V, S540R S315T L10R T76P A90V, S95T No mutation No mutation 1401 A → G N/A
78 S531L, S540R S315T E92D A28D D94G, S95T No mutation K43R No mutation N/A
87 S531L, S540R S315T E92D D12A D94G, S95T No mutation K43R No mutation N/A
94 S531L S315T E92D V139A S91P, S95T No mutation K43R 1401 A → G N/A
96 H513L S315T N/A No mutation D94N, S95T No mutation No mutation No mutation N/A
128 S531L S315T E92D Del G pos256, S179V N/A No mutation K88R 1401 A → G L11L
133* S531L S315T E92D N/A D94G, S95T No mutation K43R 1401 A → G N/A
145 L533P, S540R S315T E92D Del C pos 428 D94G, S95T No mutation K43R No mutation L11L
158 S531L S315T E92D No mutation S95T No mutation K43R 1401 A → G N/A
169 S531L, S540R S315T E92D A-11G D94Y, S95T No mutation K43R No mutation L11L
171 S531L S315T E92D No mutation S95T No mutation K43R No mutation L11L
235 S531L S315T E92D V7G A90V, S95T No mutation K43R No mutation L11L
236* S531L, S540R S315T E92D N/A D94G, S95T No mutation K43R 1401 A → G L11L
238 S531L S315T I81I, E92D V45G, I31S D94G, S95T No mutation K43R 1401 A → G L11L
275 S531L S315T E92D No mutation D94A, S95T No mutation K43R 1401 A → G L11L
276 S531L S315T N/A No mutation S95T No mutation No mutation 1401 A → G N/A
285 S531L S315T E92D L172P D94A, S95T No mutation K43R 1401 A → G L11L
287 S531L S315T N/A I31S S91P, S95T No mutation K43R 1401 A → G N/A
300 S531L, S540R S315T E92D, R102P I31S A90V, S95T No mutation K43R 1401 A→ G N/A
309 S531L, S540R S315T N/A A146T A90V, S95T No mutation K43R 1401 A → G N/A
1084 S531L, S540R S315T N/A D8N D94N, S95T No mutation K43R 1401 A → G N/A
4548 S531L S315T E92D Del A pos 353 D94G, S95T No mutation K43R 1401 A → G N/A





















In three cases it was found that isolate 145 contained
the mutation in codons L533P and S540R, whereas iso-
late 48 contained D516V and S540R. In addition, isolate
96 had the H513L substitution in the RpoB protein.
The katG gene is involved in the formation of isonia-
zid resistance. Sequencing of a fragment of this gene re-
vealed the presence of a mutation resulting in a S315T
substitution in all the DNA samples from the M. tuber-
culosis isolates (Table 3).
The rrs gene, encoding 16S ribosomal RNA, is involved
in resistance to amikacin, kanamycin and capreomycin.
Among the 30 isolates, 20 had the same nucleotide change
at position 1401 (A → G), while a G → A substitution at
position 685 was identified in one isolate (no. 15). Add-
itional mutations (Table 3, delA) were found in the inter-
genic region (between the rrs genes (RVBD 6066)
encoding 16S rRNA, and RV6067, encoding 23S rRNA) in
the nucleotide position 1473396v (no. 9). Ten isolates did
not contain any mutations in rrs. The tlyA gene, which en-
codes hemolysin, is also responsible for resistance to ami-
kacin, kanamycin and capreomycin. Analysis of sequenced
fragments of this gene showed the presence of synonym-
ous mutations (CTA33CTG, L11L) in several samples
(Table 3).
The gidB gene, encoding the ribosomal RNA small
subunit methyltransferase G, is responsible for resistance
to streptomycin. In 23 of the sequenced samples, a mu-
tation (A276C) in gidB that results in a nonsynonymous
(E92D) change in its protein product was identified; one
isolate contained the substitution R102P (no. 300), while
another contained a synonymous mutation (I81I) in
GidB. Two isolates contained the L10R substitution. In
five cases we were unable to amplify the gidB gene frag-
ment (Table 3).
In contrast, we found that the pncA gene, which en-
codes pyrazinamidase, exhibited a much higher diversity
level in the range of nonsynonymous mutations and se-
quence deletions, and only five samples did not harbor
mutations in this gene (Table 3).
The gyrA gene, which codes for the DNA gyrase sub-
unit A, is involved in ofloxacin resistance. In most cases
nonsynonymous mutations were found in the 90th, 94th,
and 95th codons of this gene. In one case we were un-
able to amplify this gene (no 128). In the gyrB gene,
which encodes the DNA gyrase subunit B, no mutations
were detected.
The rpsL gene, which encodes the ribosomal protein
S12, is responsible for streptomycin resistance. In 24
cases (80%) a mutation leading to the amino acid substi-
tution K43R was detected. In five cases no mutations
were detected (Table 3).
Taking into account the results of the antibiotic sus-
ceptibility testing (Table 2) and genotypic determination
of the mutations described above (Table 3), the status of
extensively drug-resistance (XDR TB) has been assigned
to 29 of the isolates. In addition, isolate 20 had the mu-
tation in the gyrA gene that leads to ofloxacin resistance.
Deligotyping
For deligotyping we used the following loci: RD105,
RD149, RD152, RD174, RD181, RD207, RD150, RD239,
RD702, RD711, RD724, and RD750, as described by Tso-
laki et al. [14]. Oligonucleotide primers were synthesized
so that the presence of the amplification product indi-
cated the absence of the deletion in the variable region
[10]. Using this technique, we found that 28 of the 30M.
tuberculosis clinical isolates did not contain RD105,
RD149, RD152, RD181, and RD207 loci in their ge-
nomes, thus confirming that they belonged to the Beijing
family (Table 4). The presence of RD105, RD181, and
RD207 in two of the DNA samples indicated that these
isolates belonged to other M. tuberculosis families; this
was further confirmed by VNTR typing, which showed
that these isolates belonged to the LAM family.
RD149 and RD152 loci were absent in all the 30 myco-
bacterial DNA samples analyzed. However, RD150,
RD239, RD702, RD711 and RD724 loci were found in all
of the DNA samples The Hunter–Gaston discrimination
index (HGDI) for deligotyping was equal to 0.128.
VNTR-typing
M. tuberculosis genetic families were determined using
VNTR typing and the MIRU–VNTRplus database (http://
www.miru-vntrplus.org/MIRU/index.faces) [15]. We hy-
pothesized that most of the M. tuberculosis isolates char-
acterized as having extensive drug resistance would
belong to the Beijing family. Hence, we used the 15 stand-
ard VNTR-loci proposed by Supply et al. for genotyping
[16]. For enhanced differentiation we used four additional
loci (Mtub30, Mtub39, Qub4156, V11) for closely related
isolates of the Beijing family, which proved to be highly
discriminatory [17]. It was shown that among the 30 clin-
ical isolates, 28 belonged to the Beijing family (Table 4).
Using the classification of Mokrousov [18], we identified
28 isolate types of the Beijing family: 11 isolates (39.3%)
belonged to the M11 type, 2 (7.1%) were the M2 type,
while one isolate (3.6%) was the M33 type. The remaining
14 isolates (50.0%) could not be attributed to any known
type based on this classification method; hence, they have
been labeled ‘unknown’. For each locus, the HGDI and its
associated confidence intervals was calculated (Table 5).
Additionally, the total HGDI for VNTR-typing was calcu-
lated as 0.889.
Cluster analysis by VNTR
To elucidate the phylogenetic relationships between the
M. tuberculosis isolates we constructed a MST based on
VNTR-sections (Figure 1). This tree is a branched chain
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wherein each vertex (a square with rounded corners)
represents a VNTR-type (Table 4), and the square is spe-
cified by the number of types. Vertex size is directly pro-
portional to the number of M. tuberculosis isolates with
relevant VNTR-profiles. The tops of the tree branches
are connected by edges, where the color denotes the dif-
ference between the two VNTR-types: black and blue
represents a difference in one locus, green and dark gray
represent differences in two different loci, and light gray
represents differences in three loci. On the minimum
spanning tree, we identified three clusters containing
from three to six VNTR-types on the inside; these iso-
lates differ from each other in a single copy at the locus
analyzed. Three VNTR-types (nos. 1, 2, and 3, Table 4)
had significantly different genetic profiles, and were not,
therefore, included in the MST. VNTR-types 1 and 2 are
consistent with M. tuberculosis DNA samples 15 and 48
that belong to the LAM family. VNTR-type 3 corre-
sponds to sample 158, and is referred to by us as ‘Beijing
family group unknown’. Cluster I comprised the VNTR-
types 4, 8, 9, and 10, wherein the latter corresponds to
the M2 type. Cluster II contains six VNTR-types (5, 11,
15, 16, 17, and 18): the most numerous of these (no. 15),
consisted of 10 isolates of the M11 Beijing M. tubercu-
losis family. According to the scientific literature, the M2
type is dominant in Russia, but is also found in East
Table 4 VNTR–typing and deligotyping results for 30M. tuberculosis isolates
No Beijing type RD-profile VNTR-profile VNTR - type
15 - 1,0,0,1,1,1,1,1,1,1,1,1 2,2,2,3,2,1,4,3,2,5,1,6,3,2,5,1,4,10,3 1
48 - 1,0,0,1,1,1,1,1,1,1,1,1 2,2,2,3,2,2,3,3,2,5,1,5,3,2,5,1,4,10,3 2
158 Unknown 0,0,0,1,0,0,1,1,1,1,1,1 3,2,4,3,3,2,3,3,2,5,1,5,3,3,4,4,5,10,6 3
300 Unknown 0,0,0,1,0,0,1,1,1,1,1,1 4,2,4,3,2,2,3,3,2,5,1,5,3,3,3,4,5,10,5 4
309 Unknown 0,0,0,1,0,0,1,1,1,1,1,1 4,2,4,3,2,2,3,3,2,5,1,7,3,3,3,4,5,10,5 5
145 Unknown 0,0,0,1,0,0,1,1,1,1,1,1 4,2,4,3,5,2,3,3,2,5,1,5,2,1,3,4,5,10,5 6
169 Unknown 0,0,0,1,0,0,1,1,1,1,1,1 4,2,4,3,5,2,3,3,2,5,1,5,2,1,3,4,5,10,5 6
235 Unknown 0,0,0,1,0,0,1,1,1,1,1,1 4,2,4,3,5,2,3,3,2,5,1,5,2,1,4,4,5,10,5 7
128 Unknown 0,0,0,1,0,0,1,1,1,1,1,1 4,2,4,3,5,2,3,3,2,5,1,5,2,3,3,4,5,10,5 8
236 Unknown 0,0,0,1,0,0,1,1,1,1,1,1 4,2,4,3,5,2,3,3,2,5,1,5,3,2,3,4,5,10,5 9
94 M2 0,0,0,1,0,0,1,1,1,1,1,1 4,2,4,3,5,2,3,3,2,5,1,5,3,3,3,4,5,10,5 10
133 M2 0,0,0,1,0,0,1,1,1,1,1,1 4,2,4,3,5,2,3,3,2,5,1,5,3,3,3,4,5,10,5 10
20 M33 0,0,0,1,0,0,1,1,1,1,1,1 4,2,4,3,5,2,3,3,2,5,1,6,3,3,3,4,5,10,5 11
87 Unknown 0,0,0,1,0,0,1,1,1,1,1,1 4,2,4,3,5,2,3,3,2,5,1,7,1,1,3,4,5,10,5 12
275 Unknown 0,0,0,1,0,0,1,1,1,1,1,1 4,2,4,3,5,2,3,3,2,5,1,7,2,1,3,4,5,10,5 13
238 Unknown 0,0,0,1,0,0,1,1,1,1,1,1 4,2,4,3,5,2,3,3,2,5,1,7,3,1,3,4,5,10,5 14
285 Unknown 0,0,0,1,0,0,1,1,1,1,1,1 4,2,4,3,5,2,3,3,2,5,1,7,3,1,3,4,5,10,5 14
6 M11 0,0,0,1,0,0,1,1,1,1,1,1 4,2,4,3,5,2,3,3,2,5,1,7,3,3,3,4,5,10,5 15
9 M11 0,0,0,1,0,0,1,1,1,1,1,1 4,2,4,3,5,2,3,3,2,5,1,7,3,3,3,4,5,10,5 15
17 M11 0,0,0,1,0,0,1,1,1,1,1,1 4,2,4,3,5,2,3,3,2,5,1,7,3,3,3,4,5,10,5 15
21 M11 0,0,0,1,0,0,1,1,1,1,1,1 4,2,4,3,5,2,3,3,2,5,1,7,3,3,3,4,5,10,5 15
37 M11 0,0,0,1,0,0,1,1,1,1,1,1 4,2,4,3,5,2,3,3,2,5,1,7,3,3,3,4,5,10,5 15
38 M11 0,0,0,1,0,0,1,1,1,1,1,1 4,2,4,3,5,2,3,3,2,5,1,7,3,3,3,4,5,10,5 15
78 M11 0,0,0,1,0,0,1,1,1,1,1,1 4,2,4,3,5,2,3,3,2,5,1,7,3,3,3,4,5,10,5 15
276 M11 0,0,0,1,0,0,1,1,1,1,1,1 4,2,4,3,5,2,3,3,2,5,1,7,3,3,3,4,5,10,5 15
287 M11 0,0,0,1,0,0,1,1,1,1,1,1 4,2,4,3,5,2,3,3,2,5,1,7,3,3,3,4,5,10,5 15
4548 M11 0,0,0,1,0,0,1,1,1,1,1,1 4,2,4,3,5,2,3,3,2,5,1,7,3,3,3,4,5,10,5 15
96 Unknown 0,0,0,1,0,0,1,1,1,1,1,1 4,2,4,3,6,2,2,3,2,5,1,3,3,3,3,4,5,10,5 16
171 Unknown 0,0,0,1,0,0,1,1,1,1,1,1 4,2,4,3,6,2,3,3,2,5,1,7,3,2,3,4,5,10,5 17
1084 M11 0,0,0,1,0,0,1,1,1,1,1,1 6,2,4,3,5,2,3,3,2,5,1,7,3,3,3,4,5,10,5 18
Note: Each number in the column “RD-profile” corresponds to the presence (1) or absence (0) of the region of differences (RD105, RD149, RD152, RD174, RD181,
RD207, RD150, RD239, RD702, RD711, RD724, RD750) in the corresponding part of the genomic DNA sample. Similarly, in the column “VNTR-profile” each digit
represents the number of repeats at a locus: ETRA, ETRB, ETRC, ETRD, ETRE, miru02, miru10, miru16, miru20, miru23, miru24, miru26, miru27, miru39, miru40,
Mtub30, Mtub39, Qub4156, and V11.
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Asia, albeit at a lower frequency [19]. Cluster III consists
of three VNTR-types (nos. 12, 13, and 14), which are
connected to two other types (nos. 6, and 7) at the level
of one or two VNTR-loci changes, respectively. Al-
though these VNTR-types (nos. 6, 7, 12, 13, and 14), as
based on their characteristic VNTR-profiles, belong to
the Beijing family, they did not have RD207 and RD105
regions of difference so we were unable to relate them
to any of the known classification types described by
Mokrousov [18].
Discussion
In this work, 30 isolates M. tuberculosis from 29 patients
with TB were typed. One patient had a mixed population
of M. tuberculosis genotypes. According to the scientific
literature, in regions with high rates of TB morbidity
and mortality, or in HIV-infected patients with tubercu-
losis, mixed populations of M. tuberculosis in humans
might exist [20].
In this study, we used a traditional method, VNTR-
typing, with 15 standard loci and 4 highly discriminatory
loci for closely related strains, to analyze our isolates.
Loci with the most discriminatory power were MIRU26,
MIRU39, and MIRU31. What is unusual is that V11,
Mtub30, Mtub39 and QUB4156 loci displayed relatively
low Hunter–Gaston discrimination indices; this could be
related to the distribution of certain genotypes in the Si-
berian and Far Eastern Federal Districts. The statistical
analysis showed that the Rand index for the two typing
methods was equal to 1 (i.e., the results of the deligotyp-
ing and VNTR-typing were consistent with each other).
It should be noted that HGDI for the VNTR-typing was
higher (HGDI = 0.889) than the deligotyping (HGDI =
0.128) [13]. This may be caused by an enhanced rate of
mutation in the variable tandem loci compared to re-
gions of difference [21]. Despite the low HGDI, deligo-
typing is a quick and convenient method for molecular-
epidemiological prescreening of M. tuberculosis samples,
Figure 1 Minimum spanning tree based on VNTR-typing of 30M .tuberculosis isolates using 19 polymorphic loci. Note: There are solid
line circled clusters isolates (I, II, III) with similar the genetic profile.
Table 5 Hunter-Gaston diversity indeх with confidence
intervals for each locus
Locus Diversity index Confidence interval K Max (pi)
MIRU26 0.609 0.550 - 0.667 5 0.548
MIRU39 0.574 0.501 - 0.648 4 0.613
MIRU31 0.441 0.343 - 0.539 5 0.742
MIRU27 0.385 0.291 - 0.479 4 0.774
ETRA 0.299 0.199 - 0.399 5 0.839
MIRU40 0.297 0.198 - 0.395 4 0.839
V11 0.243 0.148 - 0.338 4 0.871
MIRU10 0.187 0.099 - 0.275 4 0.903
MTUB30 0.185 0.099 - 0.271 3 0.903
ETRC 0.185 0.099 - 0.271 3 0.903
MTUB39 0.185 0.099 - 0.271 3 0.903
MIRU2 0.127 0.051 - 0.203 3 0.935
MIRU16 0.065 0.008 - 0.121 2 0.968
MIRU20 0.065 0.008 - 0.121 2 0.968
MIRU24 0.065 0.008 - 0.121 2 0.968
MIRU23 0.065 0.008 - 0.121 2 0.968
ETRD 0.065 0.008 - 0.121 2 0.968
QUB4156 0.065 0.008 - 0.121 2 0.968
ETRB 0.065 0.008 - 0.121 2 0.968
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prior to more in-depth typing of mycobacteria by other
methods.
Thus, in this study, among 30M. tuberculosis isolates, of
which 29 were characterized as XDR, 93.3% belonged to
Beijing family. We have previously shown that among iso-
lates from patients with complicated forms of progressive
pulmonary tuberculosis there is a predominance of iso-
lates of this family (i.e., 84% (37 of 44) [22]. In the present
study, the frequency of Beijing family isolates from pa-
tients with severe forms of pulmonary tuberculosis in the
city of Novosibirsk is significantly different from that in
the general population (OR 7.1, 95%CI [2.93–17.53], P <
0.0001). Our findings are consistent with those reported
in other countries; for example, in Nepal, genotyping of
XDR-TB isolates showed an overall prevalence of the
Beijing family of 69% [23]. Taken together, the above data
confirm that the Beijing family of M. tuberculosis is highly
virulent in humans.
In the resulting minimal spanning tree, the VNTR-type
15, which corresponds to the M11 type, had the largest size,
occupied a central position, which once again confirms its
position in the ancestral population structure of the Beijing
family [18]. We found that the distribution of the M11 type
in our dataset was 36%, while the M2 type was 6%. Previ-
ously, several dominant isolate types of the Beijing family
were identified that have epidemiological significance in the
Russian Federation [24]. Five types are reported to occur at
the greatest frequency, namely, M2, M8, M11, M28, and
M33 [19]. M11 is the ancestral line that dominates Eurasia
but is not found in Australia and South Africa. Isolates of
this type have high adaptability and the ability to increase
in numbers in THP-1 macrophages, as well as a high
capacity to induce synthesis of the anti-inflammatory cyto-
kine IL-10, and to induce macrophage necrosis. These
biological characteristics in mycobacteria contribute to in-
creased transmissibility and virulence, so identification of
such strains using molecular genetic techniques will con-
tribute to more effective use of drug therapy, and inform
decisions on standard molecular epidemiological-related
problems in TB. Identifying two isolates belonging to the
LAM family is not surprising. This family is widespread
and was found for the first time in Latin America, followed
by the Mediterranean Basin [25]. In Russia, this family has
the second highest incidence in the mycobacterial families
after the Beijing type; these two families (LAM and Beijing)
are associated with resistance to rifampicin and strepto-
mycin [26]. Our spanning tree analysis showed that despite
identical VNTR-profiles, isolates belonging to one cluster
had different mutations in genes associated with the forma-
tion of drug resistance. For example, nine isolates belonging
to MST No. 15 (Figure 1) have different mutations in pncA
and gyrA genes, primarily in pncA.
Another aspect of our work was focused on analyzing
drug resistance in the M. tuberculosis clinical isolates.
The scientific literature refers to this type of isolate as
pre-XDR-TB, or pre-totally drug-resistant-(TDR)-TB be-
cause the formation of resistance to additional drugs is a
result of mutational events whereby such bacteria have
become XDR and TDR, respectively. We searched for
mutations in the genomes of the M. tuberculosis isolates
that were associated with the formation of drug resist-
ance using molecular genetics methods. It is known that
the presence of non-synonymous mutations in the rrs
gene causes resistance to streptomycin, amikacin, kana-
mycin, and capreomycin, whereas such substitutions in
tlyA only confer resistance to amikacin, capreomycin
and kanamycin. Resistance to streptomycin is conferred
by non-synonymous changes in gidB and rpsL, while
ofloxacin resistance is conferred by such changes in gyrA
and gyrB. Finally, non-synonymous substitutions in
pncA, rpoB, and katG confer resistance to pyrazinamide,
rifampicin, and isoniazid, respectively.
In Siberia, a nucleotide substitution at codon 531 (S531L)
in rpoB is dominant in rifampicin-resistant isolates. Muta-
tions in other codons of this gene are less common, but are
associated with lower relative fitness in isolates carrying this
mutation compared with those carrying the wild-type gene
[27,28]. In addition, it is worth noting that there is a rela-
tionship between the minimum inhibitory concentration of
rifampicin and the presence of a mutation in the core re-
gion of rpoB. It was found that a high degree of resistance
to rifampicin (MIC ≥ 50 μg/ml) was observed in isolates
which have mutations in codons 513, 522, and 531. In con-
trast, a low degree of drug-resistance (MIC ≥ 12.5 μg/ml) is
conferred by nucleotide substitutions in codons 514, 521,
533 [29]. Mutations in codon 516 are also associated with a
high degree of resistance (MIC ≥ 64 μg/ml) [30,31]. Al-
though some studies report similar results, H526L and
H526N mutations are the exception; in these cases, the
MIC values did not exceed 8 and 16 μg/ml, respectively. A
replacement mutation (L533P) was associated with MIC >
32 μg/ml. Interestingly, Zhou et al. showed that replace-
ment mutations in codons 526, 531, 532, 533 and 563 of
rpoB in E.coli destabilize the promoter initiation complex
which correspond to a range of transcription activity at
these promoters at different growth rates [32].
The most common mutation for isoniazid resistance
in the XDR strains was at codon 315 of the katG gene,
thus correlating with the data from other studies [33].
This mutation was found among all of the isolates ana-
lyzed. Isoniazid resistance can also be caused by changes
in the ahpC, inhA, kasA and oxyR genes and it may be
necessary to study these genes to investigate the molecu-
lar basis for isoniazid resistance in our XDR M. tubercu-
losis isolates [34].
The dominant mutations in the rpsL gene, which is in-
volved in resistance to streptomycin, lead to amino acid
substitutions in codons K43R and K88R. It is worth
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noting that the mutation at codon 43 (K → R) is
strongly associated with high-level resistance to strepto-
mycin, which worsens the prognosis for patients under-
going treatment for infection with M. tuberculosis
carrying this mutation.
Resistance to the aminoglycosides amikacin and kana-
mycin and to capreomycin is thought to be associated
with mutations in the 16S rRNA gene (rrs). Mutations in
rRNA 16S (rrs) at position 1401 are associated with the
development of high resistance to these drugs, and this
mutation was common in our dataset (66%). The tlyA
gene, coding for cytotoxin/hemolysin, is involved in re-
sistance to aminoglycosides and capreomycin as well,
but analysis of this gene was not informative because
only 10 isolates had synonymous mutations (L11L).
The most common mutations for ofloxacin resistance
were in the gyrA gene at codons 94 and 90, the former
of which had the highest frequency of mutation (33%).
This is consistent with reports on XDR strains from
Pakistan, India, China, the United States, and Germany
[35-38], although in other regions different distributions
of mutations may occur [39]. While the sequence change
at codon 94 exhibited the highest variability, 63.3% of
the XDR strains had a mutation at codon 95 of the gyrA
gene; however, this mutation does not contribute to
ofloxacin resistance and instead serves as an evolution-
ary marker for classification of M. tuberculosis strains
into three principal genetic groups (PGGs) [40]. Hence,
the ACC polymorphism at codon 95 confirms the PGG1
and PGG2 grouping [41]. In contrast, we found no mu-
tations in gyrB.
The pncA gene, which encodes pyrazinamidase, hydro-
lyzes pyrazinamide to pyrazinoic acid, the latter in turn
communicates with the 30S ribosomal protein S1 (RpsA),
thus the protein cannot bind to tmRNA molecules that in-
hibit trans translation in mycobacteria [42]. It remains un-
clear why there is a variety of mutations in the absence of
any common mutations in this gene. One hypothesis that
may explain the wide variety of nucleotide substitutions is
that because its protein product is small (186 amino
acids), each mutation may adversely affect its function [3].
This requires further study.
Thus, sequence analysis of the hot spot regions of various
genetic loci revealed that the most common mutations
among the XDR isolates were S531L of RpoB, S315T of
KatG, various mutations in codon 94 of gyrA and the A90V
substitution in the GyrA protein, K43R of RpsL, and 1401
A → G of rrs for rifampicin, isoniazid, ofloxacin, strepto-
mycin and kanamycin/capreomycin resistance, respectively.
It is likely that these major mutations do not have a large
effect on bacterial fitness [28]. Other studies have also re-
ported similar mutations among XDR-TB isolates from
different countries. It is possible that the disagreement be-
tween the genotypic and phenotypic resistance to ofloxacin
and amikacin/kanamycin/capreomycin we observed may be
caused by other mutations in regions distinct from the cur-
rently known target regions in these drugs [43]. In addition,
mycobacterial cultures may also comprise a mixed popula-
tion of resistant and sensitive bacteria [44] and, therefore,
DNA extracted from specimens may contain lower levels of
the resistant genotype, leading to a false low detection rate
for the specimen. It should be noted that there are also mu-
tations that are responsible for the formation of low level
resistance to particular drugs. Nevertheless, sequencing the
regions of genes responsible for the development of resist-
ance to anti-TB drugs can be a convenient way to quickly
identify drug resistance, thus enabling selection of effective
drugs for treatment of the disease.
Conclusions
Identification of Beijing family M. tuberculosis isolates that
are extensively drug-resistant and have high transmissibil-
ity and virulence highlights the need for early and rapid
detection methods for this pathogen. Such isolates can
be characterized using VNTR-typing and deligotyping
methods. Deligotyping is a simple and convenient method
for pre-screening large numbers of samples in epidemio-
logical research, but the method has low discriminatory
power. Evaluation of genetic diversity in M. tuberculosis
strains circulating within an area will enable authorities to
adopt effective measures to prevent the spread of infec-
tion, as well as providing basic information about the rela-
tionship between genetic diversity and virulence and
immunity in the host. Armed with such information, it
may be possible to determine how genetic diversity con-
tributes to the global distribution of MDR and XDR in M.
tuberculosis. It is obvious that there are epistatic interac-
tions between the different mutations associated with the
emergence of drug resistance, the genetic environment,
and compensatory mutations, but understanding these
complex relationships will require further research. DNA
sequencing has revealed the presence of major mutations
in the genes responsible for the emergence of resistance to
the major anti-TB drugs. It is hoped that in the future,
identification of M. tuberculosis drug resistant isolates and
a description of their phenotypic properties will inform
selection of more effective drugs against TB in the com-
plex epidemiological situations that exist in Western and
Eastern Siberia.
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